Our center’s latest research has been published in Health Affairs, one of the world’s leading journals in health policy, widely recognized for its authority and high impact (2023 Impact Factor: 8.1). The article, titled “Follow-On Cancer Drugs Target Earlier Stages...
Abstract This policy brief evaluates the potential impact of Most Favored Nation (MFN) pricing on pharmaceutical innovation and patient health. We analyze MFN pricing being imposed in Medicare and Medicaid, requiring U.S. prices for already launched drugs to match the...
Abstract Prescription drugs have drawn significant policy and public attention in discussions of rising health care costs in the United States. However, their actual contribution to the growth of total health care spending remains uncertain. Drawing on data from the...
This white paper is based on the Policy Brief: International Price Differences for Drug Prescriptions. The National Review also featured Professor Philipson’s oped on the same topic. Many international drug price comparisons conclude that the U.S. has the...
Government Price Controls on Obesity Drugs This policy brief discusses the implications of proposed US price controls on drugs for both public and private payers based on the manufacturing costs of producing the medications or foreign prices. We provide an in-depth...
